文献速递泌尿生殖MR

MRI能否在主动监测中替代活检?

Is MRI ready to replace biopsy during active surveillance?
PubMed 文献 · Eur Radiol · 2024-07-04

本综述探讨多参数MRI(mpMRI)在前列腺癌主动监测(AS)全流程中的作用,包括初始分层与随访,并涉及PRECISE评分系统的应用。mpMRI对临床显著前列腺癌(csPCa)具有高阴性预测值,有力证据支持其用于诊断或确认活检时的患者选择和风险分层,但随访中评估疾病进展的研究结果不一致。MRI在AS中不能完全替代活检。

要点

  • mpMRI对临床显著前列腺癌(csPCa)具有高阴性预测值,支持用于诊断或确认活检时的患者选择和风险分层。
  • 随访中使用MRI评估疾病进展的研究结果不一致。
  • MRI在主动监测中不能完全替代活检。

核心结论

  • MRI在主动监测(AS)的患者选择、风险分层和随访中起重要作用,但由于现有局限,在AS背景下不能完全替代活检。

研究设计与样本

  • 综述,旨在探讨多参数MRI(mpMRI)在主动监测全流程(从初始分层到随访)中的作用和表现,并涉及PRECISE评分系统的应用。

诊断标准与关键数值

  • mpMRI对临床显著前列腺癌(csPCa)具有高阴性预测值,有力证据支持其用于诊断或确认活检时的患者选择和风险分层。

临床应用与阅片要点

  • mpMRI可用于主动监测(AS)患者的初始分层和随访,但不能完全替代活检。
  • 随访中使用MRI评估疾病进展的研究结果不一致,需注意现有局限。

局限性

  • 随访中使用MRI评估疾病进展的研究结果不一致。
  • 需明确MRI阴性临床显著前列腺癌(csPCa)的临床意义。
  • 需优化MRI质量。
  • 需确定双参数MRI(bpMRI)或多参数MRI(mpMRI)方案的作用。
  • 需整合人工智能(AI)以提升性能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Active surveillance (AS) is a conservative management option recommended for patients diagnosed with low-risk prostate cancer (PCa) and selected cases with intermediate-risk PCa. The adoption of prostate MRI in the primary diagnostic setting has sparked interest in its application during AS. This review aims to examine the role and performance of multiparametric MRI (mpMRI) across the entire AS pathway, from initial stratification to follow-up, also relative to the utilization of the Prostate Cancer Radiological Estimation of Change in Sequential Evaluation (PRECISE) criteria. Given the high negative predictive value of mpMRI in detecting clinically significant PCa (csPCa), robust evidence supports its use in patient selection and risk stratification at the time of diagnosis or confirmatory biopsy. However, conflicting results have been observed when using MRI in evaluating disease progression during follow-up. Key areas requiring clarification include addressing the clinical significance of MRI-negative csPCa, optimizing MRI quality, determining the role of biparametric MRI (bpMRI) or mpMRI protocols, and integrating artificial intelligence (AI) for improved performance. CLINICAL RELEVANCE STATEMENT: MRI plays an essential role in the selection, stratification, and follow up of patients in active surveillance (AS) for prostate cancer. However, owing to existing limitations, it cannot fully replace biopsies in the context of AS. KEY POINTS: Multiparametric MRI (mpMRI) has become a crucial tool in active surveillance (AS) for prostate cancer (PCa). Conflicting results have been observed regarding multiparametric MRI efficacy in assessing disease progression. Standardizing MRI-guided protocols will be critical in addressing current limitations in active surveillance for prostate cancer.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Dias AB, Woo S, Leni R, et al. Is MRI ready to replace biopsy during active surveillance? Eur Radiol. 2024. PMID: 38965093. doi:10.1007/s00330-024-10863-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。